Peapod Lane Capital LLC Invests $1.73 Million in OraSure Technologies, Inc. (NASDAQ:OSUR)

Peapod Lane Capital LLC purchased a new position in OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 479,323 shares of the medical instruments supplier's stock, valued at approximately $1,730,000. OraSure Technologies accounts for 1.7% of Peapod Lane Capital LLC's investment portfolio, making the stock its 24th biggest position. Peapod Lane Capital LLC owned approximately 0.64% of OraSure Technologies as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. BNP Paribas Financial Markets grew its stake in OraSure Technologies by 27.2% during the third quarter. BNP Paribas Financial Markets now owns 855,951 shares of the medical instruments supplier's stock valued at $3,655,000 after acquiring an additional 183,191 shares in the last quarter. Franklin Resources Inc. grew its holdings in OraSure Technologies by 28.5% during the 3rd quarter. Franklin Resources Inc. now owns 269,269 shares of the medical instruments supplier's stock valued at $1,091,000 after buying an additional 59,723 shares in the last quarter. JPMorgan Chase & Co. increased its stake in OraSure Technologies by 5.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 847,933 shares of the medical instruments supplier's stock worth $3,621,000 after acquiring an additional 46,216 shares during the last quarter. Barclays PLC raised its holdings in shares of OraSure Technologies by 182.6% during the 3rd quarter. Barclays PLC now owns 195,793 shares of the medical instruments supplier's stock worth $836,000 after acquiring an additional 126,503 shares in the last quarter. Finally, Exchange Traded Concepts LLC bought a new position in shares of OraSure Technologies during the 4th quarter valued at approximately $287,000. 93.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of OraSure Technologies from a "buy" rating to a "hold" rating in a research report on Thursday.

OraSure Technologies Stock Up 1.0 %

NASDAQ OSUR traded up $0.04 during trading hours on Monday, hitting $3.93. 356,731 shares of the company were exchanged, compared to its average volume of 831,436. OraSure Technologies, Inc. has a 52 week low of $3.52 and a 52 week high of $8.04. The stock has a 50-day moving average price of $3.81 and a 200 day moving average price of $4.04. The stock has a market cap of $293.14 million, a PE ratio of 26.20 and a beta of 0.05.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.